Celadon Pharmaceuticals PLC (GB:CEL) has released an update.
Celadon Pharmaceuticals Plc, a UK-based leader in cannabis-based medicines, has announced its first international commercial shipment to a major US customer. This marks a significant milestone, showcasing the company’s expansion capabilities, and follows a lucrative £26m European supply contract. The recent deals emphasize the global demand for Celadon’s high-quality medical cannabis products and their strong position in the international pharmaceutical market.
For further insights into GB:CEL stock, check out TipRanks’ Stock Analysis page.
